Trials / Not Yet Recruiting
Not Yet RecruitingNCT06533605
Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Initial Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study includes two parts, different part has different administration frequencies of SSGJ-706.
Detailed description
This study is a study of SSGJ-706 monotherapy in advanced Solid Tumors. This study includes two parts, different part has different administration frequencies of SSGJ-706. Part A is QW and part B is Q3W. Each part will assess the efficacy and safety of the preset several dose levels of SSGJ-706 in advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSGJ-706 | Bispecific antibody |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2025-07-30
- Completion
- 2025-08-31
- First posted
- 2024-08-01
- Last updated
- 2024-08-01
Source: ClinicalTrials.gov record NCT06533605. Inclusion in this directory is not an endorsement.